Publicacións nas que colabora con José López Miranda (14)

2024

  1. Estándares de la Sociedad Española de Arteriosclerosis 2024 para el control global del riesgo vascular

    Clínica e investigación en arteriosclerosis, Vol. 36, Núm. 3, pp. 133-194

2023

  1. Mortality reduction in older COVID-19-patients hospitalized in Spain during the second pandemic wave from the SEMI-COVID-19 Registry

    Scientific Reports, Vol. 13, Núm. 1

2022

  1. Does admission acetylsalicylic acid uptake in hospitalized COVID-19 patients have a protective role? Data from the Spanish SEMI-COVID-19 Registry

    Internal and Emergency Medicine, Vol. 17, Núm. 3, pp. 761-775

  2. SEA 2022 Standards for Global Control of Cardiovascular Risk

    Clinica e Investigacion en Arteriosclerosis, Vol. 34, Núm. 3, pp. 130-179

2021

  1. Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers withdrawal is associated with higher mortality in hospitalized patients with covid‐19

    Journal of Clinical Medicine, Vol. 10, Núm. 12

  2. Evolution of the use of corticosteroids for the treatment of hospitalised COVID-19 patients in Spain between March and November 2020: SEMI-COVID national registry

    Journal of Clinical Medicine, Vol. 10, Núm. 19

  3. Lipoprotein(a), LDL-cholesterol, and hypertension: Predictors of the need for aortic valve replacement in familial hypercholesterolaemia

    European Heart Journal, Vol. 42, Núm. 22, pp. 2201-2211

  4. Prior Treatment with Statins is Associated with Improved Outcomes of Patients with COVID-19: Data from the SEMI-COVID-19 Registry

    Drugs, Vol. 81, Núm. 6, pp. 685-695

2020

  1. Incidence of cardiovascular events and changes in the estimated risk and treatment of familial hypercholesterolemia: the SAFEHEART registry

    Revista Espanola de Cardiologia, Vol. 73, Núm. 10, pp. 828-834

2017

  1. Cost-effectiveness of a cascade screening program for the early detection of familial hypercholesterolemia

    Journal of Clinical Lipidology, Vol. 11, Núm. 1, pp. 260-271

2015

  1. Statins do not increase the risk of developing type 2 diabetes in familial hypercholesterolemia: The SAFEHEART study

    International Journal of Cardiology, Vol. 201, pp. 79-84

2014

  1. Lipoprotein(a) levels in familial hypercholesterolemia: An important predictor of cardiovascular disease independent of the type of LDL receptor mutation

    Journal of the American College of Cardiology, Vol. 63, Núm. 19, pp. 1982-1989

  2. Unanswered clinical questions in the management of cardiometabolic risk in the elderly: A statement of the Spanish society of internal medicine

    BMC Cardiovascular Disorders, Vol. 14, Núm. 1

2002

  1. Heterozygous familial hypercholesterolemia in Spain. Description of 819 non related cases

    Medicina Clinica, Vol. 118, Núm. 13, pp. 487-492